Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR

Rong Wang, Qiao-Yan Zhu, Wei-Wu Ye, Yuan Huang, Zhan-Hong Chen, Ya-Bing Zheng, Xiao Zou, Jian Wang, Dan-Lu Jiang, Xiao-Jia Wang, Zheng-Yang Xu, Wen-Ming Cao

PDF(3311 KB)
For Authors|For Editors|For Reviewers
PDF(3311 KB)
Discovery Medicine ›› 2024, Vol. 36 ›› Issue (182) : 527-537. DOI: 10.24976/Discov.Med.202436182.49
Article

Characterizing the Efficacy and Safety of Chemotherapy Plus Everolimus in HER2-Negative Metastatic Breast Cancer Harboring Altered PI3K/AKT/mTOR

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

HeighLight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2024, 36(182): 527-537 https://doi.org/10.24976/Discov.Med.202436182.49

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(3311 KB)

Accesses

Citation

Detail
Sections
Recommended
Follow Us on
Copyright © 2024.
By using this website, you agree to our Terms & Conditions and Privacy Policy.  
  • Disclaimer
    The statements, opinions and data contained in Discovery Medicine are solely those of the individual authors and contributors and not of the journal and the editor(s). Discovery Medicine stays neutral with regard to jurisdictional claims in published maps and insitutional affiliations.

    • /

    〈 〉